[go: up one dir, main page]

CY1120843T1 - Πεπτιδια me ανταγωνιστικες δραστικοτητες εναντι φυσικου cxcr4 - Google Patents

Πεπτιδια me ανταγωνιστικες δραστικοτητες εναντι φυσικου cxcr4

Info

Publication number
CY1120843T1
CY1120843T1 CY181101190T CY181101190T CY1120843T1 CY 1120843 T1 CY1120843 T1 CY 1120843T1 CY 181101190 T CY181101190 T CY 181101190T CY 181101190 T CY181101190 T CY 181101190T CY 1120843 T1 CY1120843 T1 CY 1120843T1
Authority
CY
Cyprus
Prior art keywords
peptides
activities against
against natural
competitive activities
natural cxcr4
Prior art date
Application number
CY181101190T
Other languages
English (en)
Inventor
Wolf-Georg Forssmann
Frank Kirchhoff
Jan Münch
Ludger Ständker
Original Assignee
Pharis Biotec Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharis Biotec Gmbh filed Critical Pharis Biotec Gmbh
Publication of CY1120843T1 publication Critical patent/CY1120843T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)

Abstract

Πεπτίδιο αποτελεσματικό στην αναστολή της προκαλούμενης από CXC-χημειοκίνης υποδοχέα 4 (CXCR4) HIV-1 NL4-3 (Χ4-τροπικό) μόλυνσης με IC50 τιμή μικρότερη από 50μΜ.
CY181101190T 2013-06-12 2018-11-09 Πεπτιδια me ανταγωνιστικες δραστικοτητες εναντι φυσικου cxcr4 CY1120843T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13171718 2013-06-12
EP14729370.8A EP3007717B1 (en) 2013-06-12 2014-06-12 Peptides with antagonistic activities against natural cxcr4
PCT/EP2014/062252 WO2014198834A1 (en) 2013-06-12 2014-06-12 Peptides with antagonistic activities against natural cxcr4

Publications (1)

Publication Number Publication Date
CY1120843T1 true CY1120843T1 (el) 2019-12-11

Family

ID=48578924

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181101190T CY1120843T1 (el) 2013-06-12 2018-11-09 Πεπτιδια me ανταγωνιστικες δραστικοτητες εναντι φυσικου cxcr4

Country Status (18)

Country Link
US (1) US10294272B2 (el)
EP (1) EP3007717B1 (el)
JP (1) JP6667435B2 (el)
CN (2) CN105530948B (el)
AU (1) AU2014280191B2 (el)
CA (1) CA2913387C (el)
CY (1) CY1120843T1 (el)
DK (1) DK3007717T3 (el)
ES (1) ES2699576T3 (el)
HR (1) HRP20181878T8 (el)
LT (1) LT3007717T (el)
PL (1) PL3007717T3 (el)
PT (1) PT3007717T (el)
RS (1) RS58164B1 (el)
RU (1) RU2671708C2 (el)
SI (1) SI3007717T1 (el)
SM (1) SMT201800589T1 (el)
WO (1) WO2014198834A1 (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3473262A4 (en) * 2016-06-16 2020-03-18 The University Of Tokyo PLEXIN LINK REGULATOR
AU2018328044B2 (en) * 2017-09-08 2024-03-21 Neopep Pharma Gmbh & Co. Kg Polypeptides for the treatment of diseases
CA3117875A1 (en) * 2018-11-09 2020-05-14 Neopep Pharma Gmbh & Co. Kg Polypeptides for the treatment of stress, immunoreaction and stroke syndromes
EP3872084A1 (en) * 2020-02-27 2021-09-01 Universität Ulm Epi-x4 based peptides and derivatives thereof
WO2023099725A1 (de) * 2021-12-02 2023-06-08 Pharis Biotec Gmbh Pharmazeutische zubereitung enthaltend eine mischung eines natriuretischen peptids (anp) und eines peptidischen hemmstoffs des cxcr4-rezeptors
WO2024235986A1 (en) 2023-05-15 2024-11-21 Pharis Biotec Gmbh Peptides for use in the treatment of sarcoma
EP4483892A1 (en) * 2023-06-29 2025-01-01 Pharis Biotec GmbH Composition comprising lekti polypeptides for the treatment of disorders
EP4501347A1 (en) 2023-08-02 2025-02-05 Wolf-Georg Forssmann Peptides for use in the treatment of central nervous system disorders
EP4501348A1 (en) 2023-08-02 2025-02-05 Wolf-Georg Forssmann Peptides for use in the improvement of well-being
WO2025114560A1 (en) 2023-12-01 2025-06-05 Pharis Biotec Gmbh Alb408-423 peptides for use in the treatment of cancer in combination with radiotherapy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960703136A (ko) 1993-06-09 1996-06-19 미첼 클레인 탠덤 합성 hiv-1 펩티드들
EP0967284A1 (en) 1998-05-28 1999-12-29 Pfizer Limited Phosphodiesterases
EP1171152A4 (en) * 2000-02-03 2002-09-25 Univ Jefferson VMIP-II PEPTIDE ANTAGONISTS OF CXCR4
US7390870B2 (en) * 2001-07-03 2008-06-24 Posco Immune-enhancing peptides
US20040001993A1 (en) 2002-06-28 2004-01-01 Kinkelaar Mark R. Gas diffusion layer for fuel cells
WO2004094465A2 (en) * 2003-04-23 2004-11-04 The Board Of Trustees Of The University Of Illinois Office Of Technology Management University Of Illinois At Urbana-Champaign Synthetic molecules that mimic chemokines
MXPA06014393A (es) * 2004-06-18 2007-07-04 Ipf Pharmaceuticals Gmbh Peptidos oligomericos y su uso para el tratamiento de infecciones por vih.
FR2877946B1 (fr) 2004-11-12 2011-02-11 Commissariat Energie Atomique Peptides derives de la maurocalcine utilisables comme vecteurs pour l'adressage intracellulaire de molecules d'interet
WO2007095347A2 (en) * 2006-02-13 2007-08-23 The Gov. Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Methods and compositions related to ghs-r antagonists
PT2089425E (pt) 2006-11-10 2011-10-17 Covx Technologies Ireland Ltd Compostos anti-angiogénicos
DE102007030904A1 (de) * 2007-07-03 2009-02-05 Pharis Biotec Gmbh Humanes zirkulierendes antivirales Albumin-Fragment (ALB-408) und seine Verwendung
WO2010092135A2 (en) * 2009-02-11 2010-08-19 Novozymes Biopharma Uk Ltd. Albumin variants and conjugates
AU2011218294A1 (en) 2010-02-16 2012-08-30 Medimmune, Llc HSA-related compositions and methods of use
KR20140012094A (ko) 2011-02-15 2014-01-29 메디뮨 엘엘씨 Hsa 관련 조성물 및 사용 방법
EP2564869A1 (en) * 2011-09-02 2013-03-06 Ceva Sante Animale Synthetic capsid proteins and uses thereof

Also Published As

Publication number Publication date
DK3007717T3 (da) 2019-01-02
JP2016521716A (ja) 2016-07-25
EP3007717B1 (en) 2018-08-29
JP6667435B2 (ja) 2020-03-18
HRP20181878T8 (hr) 2019-03-08
RU2671708C2 (ru) 2018-11-06
CN105530948B (zh) 2023-05-26
SI3007717T1 (sl) 2018-12-31
LT3007717T (lt) 2018-11-26
CA2913387C (en) 2024-05-21
RU2015151872A (ru) 2017-07-17
RS58164B1 (sr) 2019-03-29
CA2913387A1 (en) 2014-12-18
PL3007717T3 (pl) 2018-12-31
US20160122389A1 (en) 2016-05-05
EP3007717A1 (en) 2016-04-20
SMT201800589T1 (it) 2019-01-11
HRP20181878T1 (hr) 2019-01-11
CN105530948A (zh) 2016-04-27
CN111875670A (zh) 2020-11-03
AU2014280191B2 (en) 2018-10-11
ES2699576T3 (es) 2019-02-11
WO2014198834A1 (en) 2014-12-18
US10294272B2 (en) 2019-05-21
AU2014280191A1 (en) 2015-12-17
PT3007717T (pt) 2018-12-04

Similar Documents

Publication Publication Date Title
CY1120843T1 (el) Πεπτιδια me ανταγωνιστικες δραστικοτητες εναντι φυσικου cxcr4
EP3723675A4 (en) IMPROVEMENTS TO INCONTINENCE AID DEVICES AND CLOTHING
CY1119093T1 (el) Ανοσο-ρυθμιστικο προγονικο (imp) κυτταρο
CY1122329T1 (el) Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων
PL3727460T3 (pl) Bicykliczne ligandy peptydowe swoiste wobec epha2
CY1120729T1 (el) Πεπτιδια και συνθεσεις για τη θεραπεια τραυματισμου των αρθρωσεων
EA201690780A1 (ru) Пегилированные лекарственные средства-линкеры для улучшенной фармакокинетики конъюгатов лиганд-лекарственное средство
EP3802852A4 (en) MANIPULATED CYCLIC PEPTIDES
DK3270957T3 (da) Nyt kompleks omfattende et cellegennemtrængende peptid, en last og en tlr-peptidagonist til behandling af glioblastom
NI201300143A (es) Coagonista del receptor de glucagón/glp-1
BR112018072467A2 (pt) composições farmacêuticas com permeação aumentada
MX391916B (es) Trisiloxano organomodificado superdispersivo biodegradable
EA201690613A1 (ru) Улучшенные составы на основе аденовирусов
EP3668496A4 (en) AHR INHIBITORS AND THEIR USES
UY34419A (es) Profármaco de adrenomedulina basado en polietilenglicol y el uso del mismo
TR201901003T4 (tr) Kumaş İşleme Bileşimi
MX2016002937A (es) Vacuna oncologica.
EP3647321A4 (en) PEPTIDE FOR TOLL-TYPE RECEPTOR (TLR) INHIBITION AND PHARMACEUTICAL COMPOSITION CONSISTING OF IT
MX389178B (es) Formulacion de proporcion fija de insulina glargina/lixisenatida.
EA201700136A1 (ru) Полимерная композиция для слоя элемента слоя
CY1124041T1 (el) Συνθεσεις που περιλαμβανουν κυκλοσπορινη
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
MX389026B (es) Una composicion farmaceutica y el uso de la misma.
EP3658123A4 (en) PHARMACEUTICAL COMPOSITIONS WITH A HIGH DRUG LOAD
HUE040418T2 (hu) Antimikrobiális peptid és felhasználásai